#EULAR2022 POS0256 by @CaoilfhionnMD, @DrLisaCS, @JuliePaikMD from @HopkinsRheum 10% of pts seronegative for COVID antibodies after vaccination ⭐️Risk factors: Non-white, J&J vaccine, MMF, RTX, GC, combination Rx, not-withholding peri-vaccination immunosuppression @Rheumnow https://t.co/Izd4QJlOWH

Torgashina et al Rituximab in Sjogrens ILD. ILD first manifestation of Sjogrens in 26%. Rituximab improvement in 37% and stabilisation in 47%. @RheumNow #EULAR2022 POS0710 https://t.co/CCnPVrTGfI

#EULAR2022 OP0278: Increase in risk of CVA compared to general population ~1.2x risk ⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era ⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop @Rheumnow https://t.co/r8QsJABfvx

Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI

Pan et al. SPI-62 (11beta-hydroxysteroid dehydrogenase inhibitor) minimises steroid side effects in animal studies. Now going on to a clinical trial in PMR. Exciting as steroid adverse events are a huge problem in PMR/GCA @RheumNow #EULAR2022 POS1332 https://t.co/NEoIx971jS

Can we predict VTEs from JAKi for RA at all? Baseline elevated D-dimer pts who go on to develop VTE (but not baseline CRP, so not just general inflamm) Questions raised about effect modification for VTE following JAKi too. This story not yet done OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl

#EULAR2022 OP0277 MSK IRAE from Checkpoint inhibitors ⭐️118 pts w MSK complaints 76% w arthralgias/myalgias, 30% with inflammatory rheumatic features Most grade 1/2, 2 grade 4 (myositis) 23 (19.5%) required d/c, time of resolution ~3 mos, 20% persistence at end of study @RheumNow https://t.co/SINqmmjsLq

Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M

Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, then stop. 2 PMR flares during toc. 1 month post-stop 100% remission. 6 months post-stop 24% GCA flare! Some patients seem to need indefinite toc @RheumNow #EULAR2022 POS0266 https://t.co/8I5GQ08HDr

Long-term low-dose steroids for RA: can it be weaned? Weaning after 2y of blinded add-on in RA: either PNL 5mg/d or placebo No substantial evidence of adrenal insufficiency - symptoms same - cortisol/ACTH same It's never too late to wean the pred! OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb

🧫 JAKi and NK cells activation: JAKi and particularly TOFA impacts NK cells: *phenotype *function *impairs the control of proliferation of lung cancer and lymphoma cell lines An explanation for the increase of cancer events in ORAL surveillance? @RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU